Recent Updates
Recently added Catalysts
RARE

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

Monday, June 8, 2015 1 min read
Key Takeaway: Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

Full Press Release Details

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7.
Tags: RARE Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 8, 2015